SEL 110

Drug Profile

SEL 110

Alternative Names: SEL-110; SVP Rapamycin; SVP-R

Latest Information Update: 24 Apr 2017

Price : $50

At a glance

  • Originator Selecta Biosciences
  • Class Anti-infectives; Antifungals; Antineoplastics; Gene therapies; Lactones; Macrolides; Polyenes; Pyridines
  • Mechanism of Action Immunomodulators; Methylmalonyl CoA mutase stimulants; Ornithine carbamoyltransferase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Clinical Phase Unknown Immunological disorders
  • Research Inborn urea cycle disorders; Methylmalonic acidaemia

Most Recent Events

  • 01 Apr 2017 Pharmacodynamics data fom preclinical studies presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 27 Mar 2017 Selecta announces intention to submit IND for Methylmalonic acidaemia to US FDA in 2018
  • 31 Oct 2016 Preclinical pharmacodynamics data released by Selecta Biosciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top